1. Home
  2. Live Updates
  3. Institute of microbiology chinese academy science

Live Breaking News & Updates on Institute of microbiology chinese academy science

Stay informed with the latest breaking news from Institute of microbiology chinese academy science on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Institute of microbiology chinese academy science and stay connected to the pulse of your community

Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma - Press Release


SHANGHAI, China, July 30, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the National Medical Products Administration (NMPA) of China has accepted its supplemental New Drug Application (sNDA) for toripalimab in combination with platinum-containing chemotherapy as the first-line treatment for patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). It is the fifth NDA submitted for toripalimab in China.
The supplemental NDA is based on the JUPITER-06 study (Clinicaltrials.gov identifier: NCT03829969), which is a randomized, double-blind, placebo-controlled Phase III clinical study led by Professor Ruihua Xu from Sun Yat-sen University Cancer Center. A total of 514 patients were enrolled. The co-primary endpoints were progression-free survival (PFS) as assessed by the Blinded Independent Review Committee (BICR) and overall survival (OS). Secondary endpoints included the PFS assessed by investigator, objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and safety. Based on the results of the interim analysis, the Independent Data Monitoring Committee (IDMC) determined that the co-primary endpoints of PFS and OS have crossed the prespecified efficacy boundaries and that toripalimab combined with standard chemotherapy as the first-line treatment significantly prolonged the PFS and OS of patients with advanced or metastatic ESCC, compared with placebo combined with standard chemotherapy. Data from the JUPITER-06 study will soon be presented at the 2021 ESMO Annual Meeting.

Guangzhou , Guangdong , China , Shanghai , United-states , Suzhou , Jiangsu , Beijing , Maryland , San-francisco , California , Chinese

Junshi Biosciences and Immorna Announce Joint Venture to


Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
July 19, 2021 20:41 ET
| Source:
Junshi Biosciences
Junshi Biosciences
Shanghai, CHINA
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines


Author of the article:
GlobeNewswire
Publishing date: Jul 19, 2021  •  4 hours ago  •  4 minute read  • 
Article content
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating ...


Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating ...
Junshi BiosciencesJuly 20, 2021 GMT
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines


(1)
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.
Immorna's unique mRNA construction and established versatile process platform are suitable for the development of self-replicating mRNA as well as conventional non-replicating mRNA products, enabling the construction of a customized form of mRNA molecule for a specific disease. In terms of delivery vehicles, Immorna has developed several nanoliposome particles (LNP) suitable for different administration methods and has technical capabilities in the field of research and development of new non-LNP delivery vehicles.

China , Shanghai , Chinese , Zihao-wang , Junshi-bioscience , Junshi-biosciences , Zhili , Eli-lilly , Institute-of-microbiology-chinese-academy-science , Ir-team , Pr-team , Rna-technology-platform

Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines | Comunicados | Edición USA


20 jul 2021
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines


Junshi Biosciences
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines
SHANGHAI, China, July 20, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has established a joint venture with Immorna, a fast-growing biotechnology company focusing on the process development and optimization of mRNA and delivery vehicles and the research and development of new nucleic acid drugs, to develop and commercialize new drugs for the global market in the fields of cancer, infectious diseases, rare diseases, and other diseases, based on the mRNA technology and other technology platforms.

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer


Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company's commercialization planning and operations.
"We are delighted to have Wei join Junshi's senior leadership team," said Mr. Jun Xiong, Chairman of Junshi Biosciences. "Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences' commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world."

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Junshi Biosciences Appoints Wei Qian as Chief Commerical


Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
July 01, 2021 21:09 ET
| Source:
Junshi Biosciences
Junshi Biosciences
Shanghai, CHINA
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations.
“We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world."

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese

Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer | Comunicados | Edición USA


2 jul 2021
Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer
SHANGHAI, China, July 02, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the company has appointed Mr. Wei Qian as Chief Commercial Officer (CCO). Mr. Qian will be responsible for the company’s commercialization planning and operations.
“We are delighted to have Wei join Junshi’s senior leadership team,” said Mr. Jun Xiong, Chairman of Junshi Biosciences. “Wei has over two decades of pharmaceutical sales and marketing experience. We believe he will lead Junshi Biosciences’ commercialization to our next great milestone. By leveraging a differentiation strategy, he will advance the company to meet the unmet needs of patients in China and the world."

Guangzhou , Guangdong , China , Beijing , Maryland , United-states , Shanghai , Suzhou , Jiangsu , San-francisco , California , Chinese